Artia Global Partners LP
13F Reported Value
ⓘ$499.4M
incl. option notional
Equity Holdings
ⓘ$443.5M
Option Notional
ⓘ$55.9M
$45.7M puts / $10.2M calls
Holdings
50
Latest Filing
2026-03-31
Filing Quarter
Q1 2026
Portfolio Overview
Artia Global Partners LP disclosed 50 positions worth $499.4M in its Form 13F-HR for Q1 2026 — $443.5M in common stock plus $55.9M of put/call option positions (reported at underlying notional value, not premium at risk), led by $INSM (INSMED Inc) at 23.2% of the equity portfolio, followed by $ABVX and $INSM. During the quarter the fund opened 10 new positions and exited 15 — including a new stake in $MRNA. The portfolio is most concentrated in Healthcare (97.8% of disclosed assets). All figures are sourced directly from Artia Global Partners LP’s Form 13F-HR filing with the SEC under CIK 1937964.
AI Fund Analysis
StableSector Allocation
AUM History
Top Equity Holdings by Value
Option Positions
13F rules report options at the value of the underlying shares (notional) — not the premium paid or capital at risk. Shown separately from the equity sleeve above.
Quarterly Activity — Q1 2026
Click any card to unlockTop Holdings
- 29.4#2,409
Quality
$102.8M628,712 sh - —
Quality
$66.9M600,747 sh - 29.4#2,409
Quality
$45.7M279,700 sh - 89.3
Quality
$35.2M38,220 sh - —
Quality
$24.0M2,013,602 sh - —
Quality
$21.7M29,739 sh - —
Quality
$18.8M95,376 sh - —
Quality
$16.1M503,936 sh - 26.8
Quality
$13.7M162,990 sh - —
Quality
$12.2M124,990 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 INSMED Inc$INSM | 29.4#2,409 | $102.8M | 628,712 |
 Abivax S.A.$ABVX | — | $66.9M | 600,747 |
| INSMED Inc$INSMPUT | 29.4#2,409 | $45.7M | 279,700 |
 ELI LILLY & Co$LLY | 89.3 | $35.2M | 38,220 |
 Trevi Therapeutics, Inc.$TRVI | — | $24.0M | 2,013,602 |
 ARGENX SE$ARGX | — | $21.7M | 29,739 |
 ASTRAZENECA PLC$AZN | — | $18.8M | 95,376 |
 NewAmsterdam Pharma Co N.V.$NAMS | — | $16.1M | 503,936 |
 Dianthus Therapeutics, Inc. /DE/$DNTH | 26.8 | $13.7M | 162,990 |
 Revolution Medicines, Inc.$RVMD | — | $12.2M | 124,990 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of Artia Global Partners LP's 50 positions.
Showing top 10 of 50 holdings.
Sector Allocation
Healthcare
$433.6M
Technology
$9.9M
Full Holdings — Artia Global Partners LP (Q1 2026)
All 50 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $INSM | INSMED Inc | $102.8M | 23.2% | -8% | 29.4 |
| 2 | $ABVX | Abivax S.A. | $66.9M | 15.1% | +0% | — |
| 3 | $INSMPUT | INSMED Inc | $45.7M | — | -33% | 29.4 |
| 4 | $LLY | ELI LILLY & Co | $35.2M | 7.9% | -24% | 89.3 |
| 5 | $TRVI | Trevi Therapeutics, Inc. | $24.0M | 5.4% | +0% | — |
| 6 | $ARGX | ARGENX SE | $21.7M | 4.9% | -54% | — |
| 7 | $AZN | ASTRAZENECA PLC | $18.8M | 4.2% | -50% | — |
| 8 | $NAMS | NewAmsterdam Pharma Co N.V. | $16.1M | 3.6% | +0% | — |
| 9 | $DNTH | Dianthus Therapeutics, Inc. /DE/ | $13.7M | 3.1% | -21% | 26.8 |
| 10 | $RVMD | Revolution Medicines, Inc. | $12.2M | 2.7% | +20% | — |
| 11 |  $IONS | IONIS PHARMACEUTICALS INC | $10.8M | 2.4% | +0% | 37.1 |
| 12 |  $MRNACALL | Moderna, Inc. | $10.2M | — | NEW | 15.9 |
| 13 |  $EYPT | EyePoint, Inc. | $9.9M | 2.2% | +0% | 10.3 |
| 14 |  $DGX | QUEST DIAGNOSTICS INC | $8.0M | 1.8% | +0% | 69.1 |
| 15 |  $ALMS | ALUMIS INC. | $7.2M | 1.6% | NEW | 9.2 |
| 16 |  $VKTX | Viking Therapeutics, Inc. | $5.9M | 1.3% | -75% | — |
| 17 |  $MRK | Merck & Co., Inc. | $5.6M | 1.3% | NEW | 70.9 |
| 18 |  $TERN | Terns Pharmaceuticals, Inc. | $5.5M | 1.3% | NEW | — |
| 19 |  $JNJ | JOHNSON & JOHNSON | $5.5M | 1.3% | NEW | 72.8 |
| 20 |  $SION | Sionna Therapeutics, Inc. | $4.8M | 1.1% | +0% | — |
| 21 |  $SRRK | Scholar Rock Holding Corp | $4.7M | 1.1% | +0% | — |
| 22 |  $RAPP | Rapport Therapeutics, Inc. | $4.3M | 1.0% | +0% | — |
| 23 |  $ASND | Ascendis Pharma A/S | $4.1M | 0.9% | +0% | 41.5 |
| 24 |  $BLTE | BELITE BIO, INC | $4.0M | 0.9% | +39% | — |
| 25 |  $XENE | Xenon Pharmaceuticals Inc. | $3.8M | 0.8% | +63% | 12.9 |
| 26 |  $MLYS | Mineralys Therapeutics, Inc. | $3.7M | 0.8% | +0% | — |
| 27 |  $ROIV | Roivant Sciences Ltd. | $3.6M | 0.8% | +0% | — |
| 28 |  $PALI | PALISADE BIO, INC. | $3.5M | 0.8% | +0% | — |
| 29 |  $BIIB | BIOGEN INC. | $3.4M | 0.8% | NEW | 65.6 |
| 30 |  $PROK | PROKIDNEY CORP. | $3.2M | 0.7% | -2% | 21.3 |
| 31 |  $ABBV | AbbVie Inc. | $3.2M | 0.7% | +0% | 59.3 |
| 32 |  $UTHR | UNITED THERAPEUTICS Corp | $3.0M | 0.7% | +0% | 80.1 |
| 33 |  $DRUG | BRIGHT MINDS BIOSCIENCES INC. | $2.8M | 0.6% | +15% | — |
| 34 |  $PTGX | Protagonist Therapeutics, Inc | $2.4M | 0.5% | -0% | 24.8 |
| 35 |  $SLNO | SOLENO THERAPEUTICS INC | $2.3M | 0.5% | -87% | 46.3 |
| 36 |  $BTSG | BrightSpring Health Services, Inc. | $2.3M | 0.5% | +29% | 64.3 |
| 37 |  $TVTX | Travere Therapeutics, Inc. | $2.1M | 0.5% | +0% | 39.2 |
| 38 |  $EWTX | Edgewise Therapeutics, Inc. | $2.1M | 0.5% | NEW | — |
| 39 |  $CELC | Celcuity Inc. | $1.8M | 0.4% | +21% | — |
| 40 |  $BBIO | BridgeBio Pharma, Inc. | $1.5M | 0.3% | +0% | 31.7 |
| 41 |  $KNSA | Kiniksa Pharmaceuticals International, plc | $1.4M | 0.3% | +0% | — |
| 42 |  $CYTK | CYTOKINETICS INC | $1.1M | 0.2% | NEW | 28 |
| 43 |  $ELVN | Enliven Therapeutics, Inc. | $819,280 | 0.2% | NEW | — |
| 44 |  $PRAX | Praxis Precision Medicines, Inc. | $805,475 | 0.2% | +0% | — |
| 45 |  $TENX | TENAX THERAPEUTICS, INC. | $672,859 | 0.1% | +0% | — |
| 46 |  $KOD | Kodiak Sciences Inc. | $648,764 | 0.1% | +0% | — |
| 47 |  $NUVL | Nuvalent, Inc. | $502,005 | 0.1% | -40% | — |
| 48 |  $APGE | Apogee Therapeutics, Inc. | $495,425 | 0.1% | NEW | — |
| 49 |  $AVTX | Avalo Therapeutics, Inc. | $432,522 | 0.1% | -30% | 4.6 |
| 50 |  $PEPG | PepGen Inc. | $363,423 | 0.1% | +0% | — |
New Positions (10)
$MRNACALL Moderna, Inc.$10.2M$ALMS ALUMIS INC.$7.2M$MRK Merck & Co., Inc.$5.6M$TERN Terns Pharmaceuticals, Inc.$5.5M$JNJ JOHNSON & JOHNSON$5.5M$BIIB BIOGEN INC.$3.4M$EWTX Edgewise Therapeutics, Inc.$2.1M$CYTK CYTOKINETICS INC$1.1M$ELVN Enliven Therapeutics, Inc.$819,280$APGE Apogee Therapeutics, Inc.$495,425Exited Positions (15)
$QURE uniQure N.V.
$ALNY ALNYLAM PHARMACEUTICALS, INC.
$VTYX Ventyx Biosciences, Inc.
$PVLA PALVELLA THERAPEUTICS, INC.
$RNA Avidity Biosciences, Inc.$SLNOCALL SOLENO THERAPEUTICS INC
$UPB Upstream Bio, Inc.
$OCUL OCULAR THERAPEUTIX, INC$ABVXCALL Abivax S.A.$OCULCALL OCULAR THERAPEUTIX, INC
$ANRO Alto Neuroscience, Inc.
$LYRA Lyra Therapeutics, Inc.Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for Artia Global Partners LP including:
Track Artia Global Partners LP's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for Artia Global Partners LP and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: Artia Global Partners LP
13F Pro is an AI hedge fund tracker and stock research platform. For Artia Global Partners LP (SEC CIK: 1937964), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in Artia Global Partners LP's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.